Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
- 2011 Full-Year Non-GAAP EPS of $3.77, Excluding Certain Items; GAAP EPS of $2.02; Fourth-Quarter Non-GAAP EPS of $0.97, Excluding Certain Items; GAAP EPS of $0.49 - 2011 Full-Year Worldwide Sales Grew Four Percent to $48.0 Billion, Including Two Percent from Foreign Exchange; Fourth-Quarter Worldwide Sales Grew Two Percent to $12.3 Billion - Full-Year and Fourth-Quarter Double-Digit Global Growth for JANUVIA, JANUMET, ISENTRESS and GARDASIL - Company plans to file five major products for approval between 2012 and 2013 - 2012 Full-Year Non-GAAP EPS Target of $3.75 to $3.85, Excluding Certain Items; GAAP EPS Range of $2.04 to $2.30 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2011. $ in millions, except EPS amounts Fourth <br />Quarter <br />2011 Fourth Quarter 2010 Year Ended <br />Dec. 31, <br />2011 Year Ended Dec. 31, 2010 Sales $12,294 $12,094 $48,047 $45,987 GAAP EPS 0.49
https://www.merck.com/news/merck-announces-full-year-and-fourth-quarter-2011-financial-results/
Merck Announces Third Quarter 2011 Financial Results
Double-Digit Non-GAAP EPS Growth in Third Quarter 2011; Non-GAAP EPS of $0.94; GAAP EPS of $0.55 Worldwide Sales Growth of 8 Percent, Including 5 Percent From Foreign Exchange; Increase Driven by Pharmaceutical and Animal Health Sales Double-Digit Global Growth for JANUVIA, GARDASIL, SINGULAIR, JANUMET and ISENTRESS JUVISYNC and VICTRELIS and Other Product Launches Underway Company Raises Lower End of 2011 Non-GAAP EPS Range; Provides New Range of $3.72 to $3.76; Also Updates GAAP EPS Range to $2.03 to $2.20; Expects Full Year 2011 Revenue Growth in the Mid-Single Digit Range Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011. $ in millions, except EPS amounts Third Quarter 2011 Third <br />Quarter <br />2010 Sales $ 12,022 $ 11,125 GAAP EPS 0.55 0.11 Non-GAAP EPS that excludes items listed below 1 0.94 0.85 GAAP Net Income 2 1,692 342 Non-GAAP Net Income that excludes items
https://www.merck.com/news/merck-announces-third-quarter-2011-financial-results/
Merck Announces Second Quarter 2011 Financial Results
Double-Digit Non-GAAP EPS Growth in Second Quarter 2011: Non-GAAP EPS of $0.95; GAAP EPS of $0.65 Total Company and Pharmaceutical Sales Grow by 7 Percent, Including Foreign Exchange Double-Digit Global Growth Continues for JANUVIA, JANUMET, REMICADE, and ISENTRESS VICTRELIS and Other Product Launches Underway Company Raises Lower End of its 2011 Non-GAAP EPS Range; Provides New Range of $3.68 to $3.76; Also Updates GAAP EPS Range to $1.95 to $2.17 Company Announces New Phase of Merger Restructuring Program Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011. $ in millions, except EPS amounts Second Quarter 2011 Second Quarter 2010 Sales $ 12,151 $ 11,346 GAAP EPS 0.65 0.24 Non-GAAP EPS that excludes items listed below 1 0.95 0.86 GAAP Net Income 2 2,024 752 Non-GAAP Net Income that excludes items listed below 1, 2 2,950 2,708 Non-GAAP (generally accepted accounting
https://www.merck.com/news/merck-announces-second-quarter-2011-financial-results/
Merck Announces First Quarter 2011 Financial Results
Double-Digit EPS Growth in First Quarter 2011: Non-GAAP EPS of $0.92; GAAP EPS of $0.34 Double-Digit Global Growth for JANUVIA, JANUMET, SINGULAIR, REMICADE, NASONEX and ISENTRESS; Key Product Launches Underway Pharmaceutical, Animal Health and Consumer Care Divisions All Contributed Solid Revenue Growth Company Updates Full-Year 2011 EPS Targets: Non-GAAP EPS Range of $3.66 to $3.76; GAAP EPS Range of $2.04 to $2.39 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011. $ in millions, except EPS amounts First <br />Quarter <br />2011 First Quarter 2010 Sales $ 11,580 $ 11,422 GAAP EPS 0.34 0.09 Non-GAAP EPS that excludes items listed below 1 0.92 0.83 GAAP Net Income 2 1,043 299 Non-GAAP Net Income that excludes items listed below 1, 2 2,861 2,608 Non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.92 excludes purchase accounting
https://www.merck.com/news/merck-announces-first-quarter-2011-financial-results/
Merck Announces Fourth Quarter and Full Year 2010 Financial Results
Company Reports Double-Digit Non-GAAP EPS Growth in the Fourth Quarter Fourth Quarter Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $(0.17); Full Year 2010 Non-GAAP EPS of $3.42, Excluding Certain Items; GAAP EPS of $0.28 Continued Strong Global Growth from JANUVIA/JANUMET, SINGULAIR, ISENTRESS, REMICADE Realized More than $2 Billion in Net Synergy Savings in 2010; On Track to Reach $3.5 Billion in Annual Savings by End of 2012 Company Withdraws Previous Long-Term Non-GAAP EPS Target; Full Year 2011 Non-GAAP EPS Target of $3.64 to $3.76, Excluding Certain Items; GAAP EPS Range of $2.05 to $2.33 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses. The
https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2010-financial-results/
Merck Wins TEMODAR® Patent Infringement Lawsuit on Appeal
Merck & Co., Inc. said today that a federal appellate court ruled in its favor in a TEMODAR patent infringement suit against Barr Laboratories, an affiliate of Teva Pharmaceuticals. By a 2-1 vote, the appellate court rejected Barr's arguments and reversed a lower court ruling that the U.S. patent was unenforceable. "The court appropriately ruled that the patent for TEMODAR in the U.S. is enforceable," said Bruce N. Kuhlik, executive vice president and general counsel of Merck. "We invest heavily in R&D to discover innovative medicines like TEMODAR, and we will vigorously defend our intellectual property rights." Teva had been seeking FDA approval to sell a generic version of the 5, 20, 100, 140, 180 and 250 mg capsules of TEMODAR. In connection with Teva's prior agreement not to launch during the appeal, Merck agreed that it will not object to Teva's launch of a generic version of TEMODAR in August 2013. The U.S. patent and exclusivity periods otherwise will expire on February 2014.
https://www.merck.com/news/merck-wins-temodar-patent-infringement-lawsuit-on-appeal/
Merck Announces Third-Quarter 2010 Financial Results
Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.11, for the Quarter Strong Sales of Key Pharmaceutical Products; Solid Performance by Consumer Care and Animal Health Units New Product Launches and Progressing Pipeline Drive Business Momentum On Track to Meet Synergy Target of $3.5 Billion in Annual Savings by End of 2012 Raised Lower End of 2010 Non-GAAP EPS Target Range Due to Solid Year-to-Date Performance; Long-Term Non-GAAP EPS Growth Rate Target Reaffirmed Merck & Co., Inc. (NYSE: MRK) today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve. Third-quarter GAAP EPS was $0.11. Worldwide sales for the third quarter of 2010 were $11.1 billion. Net income1 for the third quarter was $342 million. For the first
https://www.merck.com/news/merck-announces-third-quarter-2010-financial-results/